Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2014—Zenalux Biomedical has improved measurement reproducibility in its Zenascope system by adding pressure-sensing capability to its optical probe. The system now allows users to dial in a target pressure for each measurement via the user interface. After probe-to-tissue contact is made, the user interface monitors pressure feedback from the tip of the optical probe, facilitating data collection at the desired contact pressure.
January 2014—Ventana Medical Systems launched the Ventana Gram Staining Kit. Automated for use on the Ventana BenchMark Special Stains instrument, the kit aids pathologists in the most basic classification of bacteria into gram-positive and gram-negative bacteria in fixed tissue samples.
January 2014—Norwegian molecular diagnostics company Genetic Analysis has launched its GA-map IBS Dysbiosis Test. The DNA-based test makes it possible to effectively and routinely analyze the composition of the gut microbiota (bacteria profile) and any dysbiosis. The GA-map IBS Dysbiosis Test can be run in any molecular diagnostics laboratory. Target DNA is first isolated from patient stool samples. Then conserved regions of the bacterial 16S rRNA gene are used as templates to amplify the more variable regions in-between that are
December 2013—Mettler Toledo released the latest version of its interactive, Web-based Electrode ValueBox. This downloadable electrode identification and troubleshooting toolkit features a revised electronic sensor product guide to help Mettler Toledo customers choose the right electrode, saving time and enhancing accuracy when pH and other values are critical to experiment outcomes and product consistency.
December 2013—Ventana Medical Systems has entered into an agreement with Incyte to collaborate on the development of companion diagnostic tests for Incyte’s oncology drug programs, beginning with the Incyte IDO1 inhibitor program.
December 2013—Biosearch Technologies has acquired a majority stake in LightSpeed Genomics, a company developing an innovative optical-detection solution for the life science and diagnostics industry based on its proprietary Synthetic Aperture Optics (SAO) technology. Biosearch and LightSpeed are collaborators on the development of StellarVision, a next-generation gene-expression platform optimized to work seamlessly with Biosearch’s Stellaris RNA FISH assays to detect and quantify single-molecule RNA targets within individual cells.
December 2013—The Society for Laboratory Automation and Screening, an international community of more than 15,000 scientists, engineers, researchers, technologists, and others from academic, government, and commercial laboratories, announced the opening of a European office in Brussels, Belgium. SLAS’ European office becomes the society’s third on three continents, joining operations in Shanghai, China, and its global headquarters in the United States.
December 2013—The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients and thereby allow doctors to better monitor and treat patients post-transplant. It is the first clinical validation study of this kind in Canada.
December 2013—New Purair 5 ductless fume hoods from Air Science USA feature a high level of operator protection where routine work is being carried out. The units exceed OSHA, ANSI, and all relevant international standards, operate at low noise levels, and recirculate rather than exhaust expensive conditioned or heated air into the atmosphere.
December 2013—Sequenom has announced a certified service provider program for the technical certification of selected laboratories offering research services using the Sequenom research-use-only MassArray system. Certifications cover the major research applications of the MassArray system, including iPlex genotyping, OncoCarta somatic mutation profiling, ADME PGx, and EpiTyper DNA methylation analysis.
